Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1

Status

Completed 3

Sponsor Class

INDUSTRY 3OTHER 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 3Other hematologic neoplasm 1

Conditions

Recurrence 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasm, Residual 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Bites and Stings 1

Interventions

Paclitaxel 489Carboplatin 435Gemcitabine 394Docetaxel 385Cisplatin 359pembrolizumab 343Bevacizumab 335Nivolumab 261Pemetrexed 242Capecitabine 221Dexamethasone 213Fluorouracil 211Rituximab 203Trastuzumab 193Cyclophosphamide 190Oxaliplatin 160Erlotinib Hydrochloride 147Ipilimumab 145atezolizumab 144Prednisone 144Cetuximab 142Irinotecan 139Leucovorin 130Doxorubicin 130Sorafenib 120Lenalidomide 119Bortezomib 118Sunitinib 107Everolimus 93130-nm albumin-bound paclitaxel 91

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × INDUSTRY × N,N-dicyclohexyl-isoborneol-10-sulfonamide × Clear all
NCT03340766 2024-10-17

HARBOUR

Amgen

Phase 1 Completed
31 enrolled 29 charts
Lymphoid

Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT00560794 2015-01-26

Phase II Study of the BiTE® Blinatumomab (MT103) in Patients With Minimal Residual Disease of B-precursor Acute Lymphoblastic Leukemia (ALL)

Amgen Research (Munich) GmbH

Phase 2 Completed
21 enrolled 19 charts
LymphoidOther hematologic neoplasm

Neoplasm, Residual, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT00274742 2015-01-16

Safety Study of the Bispecific T-cell Engager Blinatumomab (MT103) in Patients With Relapsed NHL

Amgen Research (Munich) GmbH

Phase 1 Completed
76 enrolled 15 charts
Lymphoid

Bites and Stings, Lymphoma, Non-Hodgkin, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡